CN103420989B - Benzodioxane derivative and application thereof - Google Patents
Benzodioxane derivative and application thereof Download PDFInfo
- Publication number
- CN103420989B CN103420989B CN201210150420.9A CN201210150420A CN103420989B CN 103420989 B CN103420989 B CN 103420989B CN 201210150420 A CN201210150420 A CN 201210150420A CN 103420989 B CN103420989 B CN 103420989B
- Authority
- CN
- China
- Prior art keywords
- base
- methyl
- diox
- nitrae
- isosorbide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical class C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 208000024732 dysthymic disease Diseases 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 106
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 78
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 27
- -1 methoxyl group Chemical group 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- 206010029350 Neurotoxicity Diseases 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- 229940050390 benzoate Drugs 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004212 difluorophenyl group Chemical group 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 229950007655 esilate Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 230000007135 neurotoxicity Effects 0.000 claims description 2
- 231100000228 neurotoxicity Toxicity 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 229950004288 tosilate Drugs 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 28
- 238000012360 testing method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 230000027455 binding Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 2
- 102000005962 receptors Human genes 0.000 abstract description 2
- 108020003175 receptors Proteins 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 48
- 238000000034 method Methods 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000013016 damping Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- QZOPRMWFYVGPAI-UHFFFAOYSA-N 1-chloroindole Chemical class C1=CC=C2N(Cl)C=CC2=C1 QZOPRMWFYVGPAI-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- OHGRDCDSBYWPEL-UHFFFAOYSA-N 1-fluoroindole Chemical class C1=CC=C2N(F)C=CC2=C1 OHGRDCDSBYWPEL-UHFFFAOYSA-N 0.000 description 5
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960002464 fluoxetine Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- AIONYFHTVMPJKV-UHFFFAOYSA-N 3-(3-bromopropyl)-5-methyl-1H-indole Chemical compound Cc1ccc2[nH]cc(CCCBr)c2c1 AIONYFHTVMPJKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- YUBXEUBNYOBJMQ-UHFFFAOYSA-N 3-(3-bromopropyl)-1h-indole Chemical class C1=CC=C2C(CCCBr)=CNC2=C1 YUBXEUBNYOBJMQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229940087098 Oxidase inhibitor Drugs 0.000 description 2
- MASVCBBIUQRUKL-UHFFFAOYSA-N POPOP Chemical compound C=1N=C(C=2C=CC(=CC=2)C=2OC(=CN=2)C=2C=CC=CC=2)OC=1C1=CC=CC=C1 MASVCBBIUQRUKL-UHFFFAOYSA-N 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 235000007715 potassium iodide Nutrition 0.000 description 2
- 229960004839 potassium iodide Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- LOAGJZNFOWAFIH-UHFFFAOYSA-N 3-(2-bromopropyl)-1h-indole Chemical class C1=CC=C2C(CC(Br)C)=CNC2=C1 LOAGJZNFOWAFIH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical group C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Benzodioxane derivative and application thereof, for having compound as shown in the formula (I) or its medically acceptable salt; Find through experiment, described Benzodioxane derivative can be applicable to preparation treatment Nervous and mental diseases medicine, and extracorporeal receptor binding tests shows, derivative involved in the present invention is to SERT and 5-HT
1Aacceptor has higher avidity.Animal test results shows, and this compounds, in acute treatment, can obviously reduce the mouse dead time, and the compound that therefore the present invention relates to has the effect for the treatment of Nervous and mental diseases, especially has therapeutic action to dysthymia disorders.
Description
Technical field
The invention belongs to medicinal chemistry art, be specifically related to a kind of Benzodioxane derivative and the application in treatment Mental disease thereof.
Background technology
Dysthymia disorders is the fourth-largest disease in the world, World Health Organization's investigation statistics is analyzed, only existing more than 8,900 ten thousand people of global Serious depression patient in 2002, and the patients with depression in the whole world has reached 3.4 hundred million, the incidence of whole world dysthymia disorders is about 3.1%, and in developed country close to about 6%, be about 3%-5% in China's depression rate, estimate that the year two thousand twenty dysthymia disorders will rise to the 2nd of the total class of disease.
The research and development of present all effective antidepressant drugs are the clinical effective medicines of two classes found before 50 years: Iricyclic antidepressants and oxidase inhibitor.Monoamine hypothesis is thought: dysthymia disorders is because the transmission of serotonin in human body and norepinephrine produces disorderly causing.On the basis of this hypothesis, think the transmission of norepinephrine and serotonin in tricyclic drugs and oxidase inhibitor energy reinforcement.But this two classes medicine they also to choline, suprarenin and histamine effect, therefore can produce a series of side effect.
Five amine reuptake inhibitors are the topmost antidepressant drugs of recent two decades, and it develops from tricyclic drugs, more safer than tricyclic drugs, and tolerance is better, has now become the main flow antidepressant drug of Clinical practice.It suppress the re-uptake of synaptic cleft serotonin, add the concentration of synaptic cleft serotonin.Although five amine reuptake inhibitors are significantly improved compared with tricyclic antidepressant in security, in curative effect and in onset speed, there is no improvement.
Although five amine reuptake inhibitors can improve synaptic cleft 5-HT level rapidly within a few hours, activate 5-HT simultaneously
1Aautoreceptor produces negative feedback inhibition effect, causes 5-HT Neural spike train to reduce, and then suppresses even to cancel the projected area such as cortex, hippocampus 5-HT level and raises, this 5-HT
1Aautoreceptor activates the negative feedback inhibition effect caused and is considered to play keying action in antidepressant drug onset deferring procedure.Administration is after 2 ~ 6 weeks, 5-HT
1Aautoreceptor desensitizes, and 5-HT neurone recovers regular discharge, thus produces antidepressant effect.
Onset postpones not only to reduce depressive patients compliance, also add its danger property of committing suiside, and therefore newly-developed antidepressant research and development are made every effort to innovate to some extent in quickening onset speed and break through.
Summary of the invention
The object of the invention is open a kind of Benzodioxane derivative, to overcome the above-mentioned defect that prior art exists.
Another object of the present invention is and the application of the open described Benzodioxane derivative of application in preparation medicament for treatment of depression.
Benzodioxane derivative of the present invention, for a kind of 3-(2-(4-((2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl) piperazine-1-base) alkyl)-1H-indole derivatives, for having compound as shown in the formula (I) or its medically acceptable salt;
Wherein:
R
1represent hydrogen, halogen, aryl, substituted aryl, C
1-5the C of alkyl or replacement
1-5alkyl;
R
2represent hydrogen, halogen, methoxyl group, cyano group, C
1-5the C of alkyl or replacement
1-5alkyl;
N is 1 or 2;
Preferably, described C
1-5alkyl is methyl, ethyl, propyl group, butyl, n-pentyl, isopentyl or neo-pentyl;
Preferably, the C of replacement
1-5alkyl is C
1-5haloalkyl or C
1-5hydroxyalkyl, preferred trifluoromethyl or methylol;
Preferably, the substituting group of the aryl of described replacement is C
1-5alkyl, C
1-5alkoxy or halogen;
Preferably, described aryl is phenyl;
Preferably, the aryl of described replacement is chlorophenyl, difluorophenyl, aminomethyl phenyl, ethylphenyl, isopropyl phenyl or p-methoxy-phenyl;
Preferably, R
1for hydrogen, methyl or phenyl;
Preferably, R
2for hydrogen, methyl, fluorine or chlorine;
Above-mentioned Benzodioxane derivative is selected from following compound or its pharmacy acceptable salt:
Code name 1:3-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The fluoro-3-of code name 2:5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The chloro-3-of code name 3:5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
Code name 4:3-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-5-Methyl-1H-indole;
Code name 5:3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The fluoro-3-of code name 6:5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The chloro-3-of code name 7:5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
Code name 8:3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-5-Methyl-1H-indole;
Code name 9:3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The fluoro-3-of code name 10:5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The chloro-3-of code name 11:5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
Code name 12:3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-5-Methyl-1H-indole;
Code name 13:3-(3-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The fluoro-3-of code name 14:5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The chloro-3-of code name 15:5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
Code name 16:3-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole;
Code name 17:3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The fluoro-3-of code name 18:5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The chloro-3-of code name 19:5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
Code name 20:3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole;
Code name 21:3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole;
The fluoro-3-of code name 22:5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The chloro-3-of code name 23:5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
Code name 24:3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole;
Described medically acceptable salt is selected from hydrochloride, hydrobromate, hydriodate, nitrate, vitriol, hydrosulfate, phosphoric acid salt, acid phosphate, acetate, lactic acid salt, Citrate trianion, tartrate, maleate, fumarate, mesylate, gluconate, saccharate, benzoate, esilate, benzene sulfonate or tosilate etc.;
The compound universal synthesis method of formula (I), comprises the steps:
Step (1): by carbon tetrabromide under triphenyl phosphine catalyst, the 3-ethyl/propyl indole alcohol derivatives shown in bromination formula (A), obtains 3-bromotrifluoromethane/propyl indole analog derivative;
Formula (A) compound, prepared by the method that document Org.Lett.6 (2004) 79-82 can be adopted to report, raw material all comes from Aladdin Reagent Company;
Step (2): at room temperature stir after the benzodioxan methyl alcohol that the compound-3 shown in formula (B) replaces and Tosyl chloride are dissolved in pyridine, reaction generates sulphonate;
Compound shown in formula (B), prepared by the method that document J.Med.Chem.36 (1993) 1520-1528 can be adopted to report, raw material all comes from Aladdin Reagent Company;
Step (3): described sulphonate and piperazine are dissolved in ethanol, temperature rising reflux reacts, synthesis benzodioxan methylpiperazine analog derivative;
Step (4): benzodioxan methylpiperazine analog derivative and 3-bromotrifluoromethane/propyl indole are dissolved in acetonitrile, add salt of wormwood and potassiumiodide, backflow, obtains target product.
Such as, can as shown in following reactions steps, synthesis the compounds of this invention:
Step (1)
Step (2)
Step (3)
Step (4)
In above-mentioned reaction expression, R
1, R
2, n defined with above-mentioned.
The present invention also provides a kind of pharmaceutical composition, comprise the compound shown in formula (I) or its medically acceptable salt and pharmaceutically acceptable auxiliary material for the treatment of significant quantity, as carrier and/or vehicle etc., this pharmaceutical composition produces the compound of the present invention of antipsycholic action or the antipsychotic composition of its medically acceptable salt containing being enough to;
The pharmaceutical composition that the present invention relates to, its per unit dosage can provide the activeconstituents of about 0.01 to 1000mg.Composition is used by any suitable approach, such as capsules per os, uses with the form parenteral of injection liquid, with the form topical application of paste or lotion, with the form rectal administration of suppository, with the form applied dermally of the transfer system of paster.
Compound of the present invention or its medically acceptable salt, by the form of pharmaceutical composition, put on the patient needing treatment, these preparations should contain the active compound of the present invention of at least 0.5wt%, but can change according to specific formulation, account for unit weight 4% is easily to about 70%, in such composition.The amount of active compound should reach suitable dosage.The oral dosage of the composition that the present invention is preferential and preparation contains the active compound of the present invention of 1.0-300 milligram.
Dosage of the present invention, depends on type and the seriousness of disease or illness, also depends on the feature of object, such as general health, age, sex, body weight and drug tolerance.Technician can determine suitable dosage according to these or other factors.The effective dose of medicine for central nervous system usually used is known by the technical staff.Every TDD is usually about between 0.05mg to 2000mg.
Compound of the present invention can contain chiral centre, and can exist with different enantiomorph and diastereomer form thus.The present invention relates to all optically active isomers of the compounds of this invention and all steric isomers, as the racemic mixture of this compounds and the form of each enantiomorph and diastereomer, and the present invention relate separately to as above-mentioned define containing or use their all pharmaceutical compositions and methods for the treatment of.
In addition, derivative provided by the invention and the pharmaceutical composition be made up of derivative, can be applicable to preparation treatment or prevention Nervous and mental diseases medicine aspect, described Nervous and mental diseases is selected from mental disorder, anxiety disorder, personality disorder, dysthymia disorders, manic disorder, migraine, epilepsy or convulsive disorder, childhood disorder, Parkinson's disease, cognitive disorder, neurodegeneration, neurotoxicity and local asphyxia; Preferred dysthymia disorders.
Extracorporeal receptor binding tests shows, derivative involved in the present invention is to SERT and 5-HT
1Aacceptor has higher avidity.
Animal test results shows, and this compounds, in acute treatment, can obviously reduce the mouse dead time, and the compound that therefore the present invention relates to has the effect for the treatment of Nervous and mental diseases, especially has therapeutic action to dysthymia disorders.
Embodiment
The following examples just for the purpose of description and not as restriction of the present invention.Except as otherwise noted, all temperature are centigradetemperature (DEG C).
The embodiment of A, synthesis aspect
Embodiment 1
3-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles (code name: 1)
1) triphenylphosphine of 0.025mol is dissolved in the acetonitrile of 80ml drying, drips acetonitrile (75ml) solution of 0.02mol3-(2-bromotrifluoromethane)-1H-indoles.Then, drip acetonitrile (25ml) solution of 0.027mol carbon tetrabromide, stir 3 hours at normal temperatures, except desolventizing, column chromatography, obtains pale yellow oil.
2) 1.98g (2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl alcohol is dissolved in the pyridine of 30ml drying, is cooled to 0 DEG C, adds 6.9g Tosyl chloride, stirs, and at room temperature reacts 18 hours.After having reacted, reaction solution 300ml ether dilution, with dilute hydrochloric acid washing, washing, organic over anhydrous dried over mgso, removing ether obtains white solid, and column chromatography (sherwood oil: ethyl acetate=4:1) obtains yellow oil.
3) 2.24g (2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl 4-aminomethyl phenyl sulphonate is dissolved in 20ml ethanol, add 11.9g piperazine, temperature rising reflux reacts, and reacts 36 hours, after having reacted, except desolventizing, residuum adds the sodium hydroxide solution that 50ml weight concentration is 2.5%, with chloroform extraction, organic over anhydrous dried over mgso, except desolventizing obtains yellow oily liquid, obtain faint yellow solid after cooling, fusing point: 213-216 DEG C (hydrochloride).
4) 0.4g1-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methylpiperazine is dissolved in 10ml anhydrous acetonitrile, add 0.5g3-(2-bromotrifluoromethane)-1H-indoles, 0.9g Anhydrous potassium carbonate, 0.35g potassiumiodide, temperature rising reflux, reacts 10 hours.Cooling, filter, filtrate desolventizes to obtain crude product, and crude product column chromatography (sherwood oil: ethyl acetate=1:1, volume ratio) obtains target compound.
Fusing point: 238 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.97(s,1H),7.63-7.02(m,5H),6.94-6.82(m,4H),4.55-4.32(m,2H),4.07-3.98(m,1H),3.74-3.29(m,12H),3.20-3.09(m,2H);
MS(ESI)m/z378.1([M+H]
+)。
Embodiment 2
The fluoro-3-of 5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles (code name: 2)
3-(2-bromotrifluoromethane)-1H-indoles is changed to the fluoro-1H-indoles of 3-(2-bromotrifluoromethane)-5-, prepares target compound by the method for embodiment 1.
Fusing point: 223 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.10(s,1H),7.48-7.30(m,3H),6.99-6.83(m,5H),4.72-4.31(m,2H),4.08-4.00(m,1H),3.88-3.28(m,12H),3.22-3.08(m,2H)
MS(ESI)m/z396.1([M+H]
+)
Embodiment 3
The chloro-3-of 5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles (code name: 3)
3-(2-bromotrifluoromethane)-1H-indoles is changed to the chloro-1H-indoles of 3-(2-bromotrifluoromethane)-5-, prepares target compound by the method for embodiment 1.
Fusing point: 225 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.20(s,1H),7.72-7.08(m,4H),6.96-6.85(m,4H),4.67-4.31(m,2H),4.08-4.00(m,1H),3.88-3.28(m,12H),3.20-3.12(m,2H)
MS(ESI)m/z412.0([M+H]
+)。
Embodiment 4
3-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-5-Methyl-1H-indole (code name: 4)
3-(2-bromotrifluoromethane)-1H-indoles is changed to 3-(2-bromotrifluoromethane)-5-Methyl-1H-indole, prepares target compound by the method for embodiment 1.
Fusing point: 226 DEG C, (hydrochloride decomposes);
1H-NMR(DMSO-d6)δ10.85(s,1H),7.41-7.18(m,3H),6.96-6.85(m,5H),4.72-4.31(m,2H),4.08-4.00(m,1H),3.88-3.28(m,12H),3.26-3.03(m,2H),2.39(s,3H);
MS(ESI)m/z392.1([M+H]
+)。
Embodiment 5
3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles (code name: 5)
(2,3-dihydrobenzos [b] [Isosorbide-5-Nitrae] diox-3-base) methyl alcohol is changed to (2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl alcohol, prepares target compound by the method for embodiment 1.
Fusing point: 234 DEG C, (hydrochloride decomposes);
1H-NMR(DMSO-d6)δ10.97(s,1H),7.63-7.23(m,5H),6.96-6.85(m,4H),4.49-4.41(m,1H),4.21-4.15(m,1H),3.88-3.28(m,12H),3.22-3.10(m,2H),1.37-1.20(m,3H);
MS(ESI)m/z392.1([M+H]
+)
Embodiment 6
The fluoro-3-of 5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles (code name: 6)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-methyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to the fluoro-1H-indoles of 3-(2-bromotrifluoromethane)-5-, prepares target compound by the method for embodiment 1.
Fusing point: 232 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.10(s,1H),7.48-7.30(m,3H,),6.99-6.83(m,5H),4.49-4.41(m,1H),4.21-4.15(m,1H),3.88-3.28(m,12H),3.22-3.09(m,2H),1.38-1.21(m,3H);
MS(ESI)m/z411.1([M+H]
+)
Embodiment 7
The chloro-3-of 5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles (code name: 7)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-methyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to the chloro-1H-indoles of 3-(2-bromotrifluoromethane)-5-, prepares target compound by the method for embodiment 1.
Fusing point: 234 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.19(s,1H),7.70-7.07(m,4H),6.93-6.81(m,4H),4.47-4.40(m,1H),4.20-4.12(m,1H),3.88-3.28(m,12H),3.16-3.02(m,2H),1.37-1.20(m,3H);
MS(ESI)m/z426.1([M+H]
+)
Embodiment 8
3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-5-Methyl-1H-indole (code name: 8)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-methyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to 3-(2-bromotrifluoromethane)-5-Methyl-1H-indole, prepares target compound by the method for embodiment 1.
Fusing point: 221 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.83(s,1H),7.4-7.18(m,3H),6.99-6.83(m,5H),4.49-4.41(m,1H),4.21-4.15(m,1H),3.88-3.28(m,12H),3.19-3.08(m,2H),2.39(s,3H),1.38-1.21(m,3H);
MS(ESI)m/z406.1([M+H]
+)
Embodiment 9
3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles (code name: 9)
(2,3-dihydrobenzos [b] [Isosorbide-5-Nitrae] diox-3-base) methyl alcohol is changed to (2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox 3-yl) methyl alcohol, prepares target compound by the method for embodiment 1.
Fusing point: 213 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.98(s,1H),7.66-7.18(m,8H),7.14-6.83(m,6H),5.17-5.09(m,1H),4.83-4.63(m,1H),3.88-3.28(m,12H),3.26-3.11(m,2H);
MS(ESI)m/z454.3([M+H]
+)
Embodiment 10
The fluoro-3-of 5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles (code name: 10)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-phenyl benzo [b] [1,4] diox 3-yls) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to the fluoro-1H-indoles of 3-(2-bromotrifluoromethane)-5-and prepares target compound by the method for embodiment 1.
Fusing point: 205 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.10(s,1H),7.64-7.29(m,8H),7.10-6.83(m,5H),5.17-5.09(m,1H),4.83-4.63(m,1H),3.88-3.28(m,12H),3.25-3.10(m,2H);
MS(ESI)m/z472.2([M+H]
+).
Embodiment 11
The chloro-3-of 5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles (code name: 11)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-phenyl benzo [b] [1,4] diox 3-yls) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to the chloro-1H-indoles of 3-(2-bromotrifluoromethane)-5-and prepares target compound by the method for embodiment 1.
Fusing point: 219 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.08(s,1H),7.61-7.24(m,8H),7.11-6.82(m,5H),5.17-5.09(m,1H),4.83-4.63(m,1H),3.88-3.28(m,12H),3.26-3.11(m,2H);
MS(ESI)m/z488.2([M+H]
+)
Embodiment 12
3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-5-Methyl-1H-indole (code name: 12)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-phenyl benzo [b] [1,4] diox 3-yls) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to 3-(2-bromotrifluoromethane)-5-Methyl-1H-indole and prepares target compound by the method for embodiment 1.
Fusing point: 203 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.10(s,1H),7.61-7.10(m,8H),7.11-6.82(m,5H),5.17-5.09(m,1H),4.83-4.63(m,1H),3.88-3.28(m,12H),3.18-3.10(m,2H),2.38(s,3H);
MS(ESI)m/z468.3([M+H]
+)
Embodiment 13
3-(3-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles (code name: 13)
3-(2-bromotrifluoromethane)-1H-indoles is changed to 3-(2-bromopropyl)-1H-indoles and prepares target compound by the method for embodiment 1.
Fusing point: 244 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.87(s,1H),7.54-7.02(m,5H),6.94-6.82(m,4H),4.72-4.29(m,2H),4.07-3.98(m,1H),3.74-3.29(m,10H),3.27-3.10(m,2H),2.75(t,2H,J=14.8Hz),2.16-2.04(m,2H);
MS(ESI)m/z392.1([M+H]
+)
Embodiment 14
The fluoro-3-of 5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles (code name: 14)
3-(2-bromotrifluoromethane)-1H-indoles is changed to the fluoro-1H-indoles of 3-(3-bromopropyl)-5-and prepares target compound by the method for embodiment 1.
Fusing point: 252 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.98(s,1H),7.36-7.26(m,3H,),6.99-6.83(m,5H),4.68-4.29(m,2H),4.08-4.00(m,1H),3.74-3.22(m,10H),3.26-3.03(m,2H),2.72(t,2H,J=14.8Hz),2.13-2.01(m,2H);
MS(ESI)m/z410.1([M+H]
+)
Embodiment 15
The chloro-3-of 5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles (code name: 15)
3-(2-bromotrifluoromethane)-1H-indoles is changed to the chloro-1H-indoles of 3-(3-bromopropyl)-5-and prepares target compound by the method for embodiment 1.
Fusing point: 247 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.10(s,1H),7.60-7.05(m,4H),6.95-6.83(m,4H),4.66-4.29(m,2H),4.06-3.99(m,1H),3.88-3.28(m,10H),3.24-3.06(m,2H),2.72(t,2H,J=14.8Hz),2.13-2.01(m,2H);
MS(ESI)m/z426.0([M+H]
+)
Embodiment 16
3-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole (code name: 16)
3-(2-bromotrifluoromethane)-1H-indoles is changed to 3-(3-bromopropyl)-5-Methyl-1H-indole and prepares target compound by the method for embodiment 1.
Fusing point: 244 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.72(s,1H),7.32-7.13(m,3H),6.96-6.85(m,5H),4.71-4.30(m,2H),4.07-3.99(m,1H),3.84-3.28(m,10H),3.24-3.12(m,2H),2.73(t,2H,J=14.8Hz),2.13-2.01(m,2H),2.39(s,3H);
MS(ESI)m/z406.1([M+H]
+)
Embodiment 17
3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles (code name: 17)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-methyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to 3-(3-bromopropyl)-1H-indoles and prepares target compound by the method for embodiment 1.
Fusing point: 240 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.86(s,1H),7.54-7.07(m,4H),6.98-6.82(m,5H),4.48-4.39(m,1H),4.21-4.12(m,1H),3.88-3.28(m,10H),3.23-3.09(m,2H),2.75(t,2H,J=14.8Hz),2.15-2.01(m,2H),1.38-1.18(m,3H);
MS(ESI)m/z406.1([M+H]
+)
Embodiment 18
The fluoro-3-of 5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles (code name: 18)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-methyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to the fluoro-1H-indoles of 3-(3-bromopropyl)-5-and prepares target compound by the method for embodiment 1.
Fusing point: 249 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.00(s,1H),7.37-7.26(m,3H),6.99-6.83(m,5H),4.49-4.41(m,1H),4.21-4.15(m,1H),3.88-3.28(m,10H),3.26-3.05(m,2H),2.72(t,2H,J=14.8Hz),2.14-2.02(m,2H),1.36-1.20(m,3H);
MS(ESI)m/z424.1([M+H]
+)
Embodiment 19
The chloro-3-of 5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles (code name: 19)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-methyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to the chloro-1H-indoles of 3-(3-bromopropyl)-5-and prepares target compound by the method for embodiment 1.
Fusing point: 245 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.10(s,1H),7.60-7.05(m,4H),6.99-6.83(m,4H),4.47-4.41(m,1H),4.21-4.15(m,1H),3.88-3.28(m,10H),3.23-3.05(m,2H),2.73(t,2H,J=14.8Hz)，2.14-2.02(m,2H),1.38-1.21(m,3H);
MS(ESI)m/z440.1([M+H]
+)
Embodiment 20
3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole (code name: 20)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-methyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to 3-(3-bromopropyl)-5-Methyl-1H-indole and prepares target compound by the method for embodiment 1.
Fusing point: 239 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.73(s,1H),7.43-7.16(m,3H,),7.05-6.83(m,5H),4.49-4.41(m,1H),4.21-4.15(m,1H),3.88-3.28(m,10H),3.29-3.03(m2H),2.73(t,2H,J=14.8Hz),2.39(s,3H),2.14-2.02(m,2H),1.38-1.21(m,3H);
MS(ESI)m/z420.1([M+H]
+)
Embodiment 21
3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole (code name: 21)
(2,3-dihydrobenzos [b] [Isosorbide-5-Nitrae] diox-3-base) methyl alcohol is changed to (2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl alcohol, prepares target compound by the method for embodiment 1.
Fusing point: 214 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.98(s,1H),7.63-7.15(m,8H),7.11-6.82(m,6H),5.17-5.09(m,1H),4.83-4.63(m,1H),3.88-3.28(m,10H),3.23-3.08(m,2H),2.74(t,2H,J=14.8Hz),2.14-2.02(m,2H);
MS(ESI)m/z468.3([M+H]
+)
Embodiment 22
The fluoro-3-of 5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles (code name: 22)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-phenyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to 3-(3-bromopropyl)-1H-indoles and prepares target compound by the method for embodiment 1.
Fusing point: 234 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.97(s,1H),7.61-7.24(m,8H),7.11-6.82(m,5H),5.17-5.09(m,1H),4.83-4.63(m,1H),3.88-3.28(m,10H),3.14-3.04(m,2H),2.70(t,2H,J=14.8Hz),2.10-1.96(m,2H);
MS(ESI)m/z486.3([M+H]
+)
Embodiment 23
The chloro-3-of 5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles (code name: 23)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-phenyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to the chloro-1H-indoles of 3-(3-bromopropyl)-5-and prepares target compound by the method for embodiment 1.
Fusing point: 228 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ11.08(s,1H),7.61-7.24(m,8H),7.11-6.82(m,5H),5.17-5.09(m,1H),4.83-4.63(m,1H),3.88-3.28(m,10H),3.22-3.03(m,2H),2.72(t,2H,J=14.8Hz),2.10-1.96(m,2H);
MS(ESI)m/z502.2([M+H]
+)
Embodiment 24
3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole (code name: 24)
By (2,3-dihydrobenzo [b] [1,4] diox-3-bases) methyl alcohol is changed to (2,3-dihydro-2-phenyl benzo [b] [1,4] diox-3-bases) methyl alcohol, 3-(2-bromotrifluoromethane)-1H-indoles is changed to 3-(3-bromopropyl)-5-Methyl-1H-indole and prepares target compound by the method for embodiment 1.
Fusing point: 221 DEG C, (hydrochloride decomposes).
1H-NMR(DMSO-d6)δ10.71(s,1H),7.61-7.10(m,8H),7.11-6.82(m,5H),5.17-5.09(m,1H),4.83-4.63(m,1H),3.88-3.28(m,10H),3.22-3.10(m,2H),2.70(t,2H,J=14.8Hz)2.11-1.92(m,2H),2.38(s,3H);
MS(ESI)m/z482.3([M+H]
+)
Preferred compound numbering prepared by table 1 embodiment and structural formula thereof
The embodiment of B, pharmacology aspect
Execute example 25
5HT
1Athe preparation of film
Rat breaks end, and operates on ice, gets cortex rapidly, add 3ml damping fluid (the Tris-HCl damping fluid of 0.05M, the xitix containing 0.1%, 10um Supirdyl and 4mMCaCl
2) in 4 grades of 3-4s homogenate, homogenate 4 times, then adds 5ml damping fluid, in 37 DEG C of hatching 10min, hatch rear test tube balance and adjusted weight, at 12000r, 4 DEG C of centrifugal 20min, abandon supernatant liquor, add 5ml damping fluid, mix with vortex mixer, centrifugal, in triplicate, centrifugal complete, abandon supernatant liquor ,-80 DEG C will be deposited in and store for future use.
Receptor Binding Assay material:
Isotropic substance aglucon
3h-8-OH-DPAT(67.0Ci/mmol), purchased from PerkinElmer company; 5-HT, purchased from RBI company; GF/C glass fiber filter paper, purchased from Whatman company; Tris import packing; PPO, POPOP are purchased from Shanghai reagent one factory; Fat-soluble scintillation solution.BeckmanLS-6500 type full-service fluid scintillation counter.
Experimental technique:
(1) the appropriate homogenate of film first will prepared, is uniformly dispersed with refiner, is mixed in the container of 100ml by 15 test tubes, adds the suspension that appropriate homogenate is 50ml film, for subsequent use.
(2) each reaction tubes adds film preparation thing 100 μ L respectively, homogenate 100 μ L.
(3) total binding pipe (TB) adds 100 μ L homogenates, and non-specific binding pipe (NB) adds 5-HT100 μ L(final concentration 10
-5m), each test-compound specific binding pipe (SB) adds 100 μ L test-compound (final concentrations 10
-5m);
(4) each reaction tubes adds radioligand respectively
3the each reaction tubes of H-8-OH-DPAT10 μ L(all establishes 3 parallel pipes, and during application of sample, each pipe is placed on ice);
(5) each reaction tubes 37 DEG C of temperature are incubated 10min, react complete, in conjunction with aglucon by decompression fast filtering, fully wash with ice-cold test damping fluid, by filter disc take out be put in 3ml scintillating disc, add the toluene scintillation solution of 2ml and mix;
(6) scintillation vial is put into liquid scintillation counter counting.
Inhibiting rate (I%)=(total binding pipe cpm-compound cpm)/(total binding pipe cpm-non-specific binding pipe cpm) × 100%
Compound is tested at every turn and is done three parallel samples.
Experimental result is in table 2
Execute example 26
The preparation of SERT film
Rat breaks end, and operates on ice, gets cortex rapidly, add 3ml damping fluid (the Tris-HCl damping fluid of 0.05M, containing NaCl120mM, KCl5mM) in 4 grades of 3-4s homogenate, homogenate 4 times, then adds 5ml damping fluid, in 23 DEG C of hatching 10min, hatch rear test tube balance and adjusted weight, at 12000r, 4 DEG C of centrifugal 20min, abandon supernatant liquor, add 5ml damping fluid, with vortex mixer mixing, centrifugal, in triplicate, centrifugal complete, abandon supernatant liquor ,-80 DEG C will be deposited in and store for future use.
Receptor Binding Assay material:
Isotropic substance aglucon [
3h]-paroxetine, purchased from PerkinElmer company; Paroxetine, purchased from sigma-aldrich company; GF/C glass fiber filter paper, purchased from Whatman company; Tris import packing; PPO, POPOP are purchased from Shanghai reagent one factory; Fat-soluble scintillation solution.BeckmanLS-6500 type full-service fluid scintillation counter.
Experimental technique:
(1) the appropriate homogenate of film first will prepared, is uniformly dispersed with refiner, is mixed in the container of 100ml by 15 test tubes, adds the suspension that appropriate homogenate is 50ml film, for subsequent use;
(2) each reaction tubes adds film preparation thing 100 μ L respectively, homogenate 100 μ L;
(3) total binding pipe (TB) adds 100 μ L homogenates, and non-specific binding pipe (NB) adds paroxetine100 μ L(final concentration 10
-5m), each test-compound specific binding pipe (SB) adds 100 μ L test-compound (final concentrations 10
-5m);
(4) each reaction tubes adds radioligand respectively
3the each reaction tubes of H-paroxetine10 μ L(all establishes 3 parallel pipes, and during application of sample, each pipe is placed on ice);
(5) each reaction tubes 23 DEG C of temperature are incubated 60min, react complete, in conjunction with aglucon by decompression fast filtering, fully wash with ice-cold test damping fluid, by filter disc take out be put in 3ml scintillating disc, add the toluene scintillation solution of 2ml and mix;
(6) scintillation vial is put into liquid scintillation counter counting.
Inhibiting rate (I%)=(total binding pipe cpm-compound cpm)/(total binding pipe cpm-non-specific binding pipe cpm) × 100%
Compound is tested at every turn and is done three parallel samples.
Experimental result is in table 2.
Vitro Experimental Results shows that compound 1 and 6 is to two kinds of acceptor (5HT
1Aand SERT) stronger avidity.
Embodiment 27
Tail suspension test
Laboratory animal and reagent
Healthy Kunming mouse, male and female half and half, body weight (20 ± 2) g, is provided by Qinglongshan animal cultivation center, Nanjing.
Fluoxetine, sigma-aldrich company;
Experimental technique
Experiment a few days ago filters out the qualified mouse of body weight and divides into groups, mouse is put into 6min on lever by D1, the dead time of 4min after record, filter out the dead time the mouse of 60s ~ 180s and set up 60s ~ 90s, 90s ~ 120s, then 120s ~ 180s tetra-levels carry out random packet mouse at all levels, often organize 10, set up blank group, positive controls and be subject to each administration group of reagent.D2, after mouse stomach administration 1h, is put into 6min on lever by mouse, the dead time of 4min after record.
Motionless standard: what is called is motionless refers to that mouse static stopping on lever is struggled or presented the state of playing on a swing.
Obtain the mean value of each group of mouse dead time, result represents with " means standard deviation ", the result of administration group and control group is carried out t and checks whether there is antidepressant, with P<0.05 for there being significant difference to evaluate test medicine.
Experimental result is in table 2.
Observe by experiment, the compound 1 and 6 gastric infusion 80mg/kg dead time significantly reduces.Compared with blank, the dead time of compound 1 reduces 63.4%, and its action effect is better than fluoxetine, and the dead time of compound 6 reduces 54.4%, and its action effect is suitable with fluoxetine.
Table 2 compound is to the IC of each acceptor
50
Table 3 compound is on the impact of Tail suspension test dead time
| Compound | Dosage (mg/kg) | Dead time (s) |
| Blank | 108 | |
| Fluoxetine | 80 | 48.8±4.2 |
| 1 | 80 | 39.5±4.2 |
| 2 | 80 | 79.9±4.7 |
| 5 | 80 | 71.1±6.2 |
| 6 | 80 | 49.2±5.3 |
| 13 | 80 | 93.2±3.5 |
| 14 | 80 | 95.5±4.4 |
| 21 | 80 | 63.0±4.1 |
C, composition embodiment
Embodiment 28
It is for subsequent use that supplementary material crosses 80 mesh sieves; take recipe quantity activeconstituents, Microcrystalline Cellulose, lactose, PVP K30, join in high-speed mixing granulating machine, stirring at low speed mixes; add appropriate purified water; stirring at low speed, high-speed cutting is granulated, wet granular 60 DEG C of dry 3h; the whole grain of 24 mesh sieve; add recipe quantity carboxymethylstach sodium, silicon-dioxide and Magnesium Stearate, always mix, rotary tablet machine compressing tablet.
Embodiment 29
It is for subsequent use that supplementary material crosses 80 mesh sieves; take recipe quantity activeconstituents, lactose, starch, PVP K30, join in high-speed mixing granulating machine, stirring at low speed mixes; add appropriate purified water; stirring at low speed, high-speed cutting is granulated, wet granular 60 DEG C of dry 3h; the whole grain of 24 mesh sieve; add recipe quantity silicon-dioxide and Magnesium Stearate, always mix, capsule filling machine filled capsules.
Claims (11)
1. Benzodioxane derivative, is characterized in that, for having such as formula the compound shown in (I) or its medically acceptable salt;
Wherein:
R
1represent hydrogen, halogen, aryl, substituted aryl, C
1-5the C of alkyl or replacement
1-5alkyl;
R
2represent hydrogen, halogen, methoxyl group, cyano group, C
1-5the C of alkyl or replacement
1-5alkyl;
N is 1 or 2;
The substituting group of described substituted aryl is C
1-5alkyl, C
1-5alkoxy or halogen;
Described aryl is phenyl;
The C of described replacement
1-5alkyl is C
1-5haloalkyl or C
1-5hydroxyalkyl.
2. Benzodioxane derivative according to claim 1, is characterized in that, the aryl of described replacement is chlorophenyl, difluorophenyl, aminomethyl phenyl, ethylphenyl, isopropyl phenyl or p-methoxy-phenyl.
3. Benzodioxane derivative according to claim 1, is characterized in that, described C
1-5alkyl is methyl, ethyl, propyl group, butyl, n-pentyl, isopentyl or neo-pentyl.
4. Benzodioxane derivative according to claim 1, is characterized in that, the C of described replacement
1-5alkyl is C
1-5haloalkyl is trifluoromethyl.
5. Benzodioxane derivative according to claim 1, is characterized in that, described C
1-5hydroxyalkyl is methylol.
6. Benzodioxane derivative according to claim 1, is characterized in that, R
1for hydrogen, methyl or phenyl, R
2for hydrogen, methyl, fluorine or chlorine.
7. Benzodioxane derivative according to claim 1, is characterized in that, is selected from following compound or its pharmacy acceptable salt:
Code name 1:3-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The fluoro-3-of code name 2:5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The chloro-3-of code name 3:5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
Code name 4:3-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-5-Methyl-1H-indole;
Code name 5:3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The fluoro-3-of code name 6:5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The chloro-3-of code name 7:5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
Code name 8:3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-5-Methyl-1H-indole;
Code name 9:3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The fluoro-3-of code name 10:5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
The chloro-3-of code name 11:5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-1H-indoles;
Code name 12:3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) ethyl)-5-Methyl-1H-indole;
Code name 13:3-(3-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The fluoro-3-of code name 14:5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The chloro-3-of code name 15:5-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
Code name 16:3-(2-(4-((2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole;
Code name 17:3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The fluoro-3-of code name 18:5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The chloro-3-of code name 19:5-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
Code name 20:3-(2-(4-((2,3-dihydro-2-methyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole;
Code name 21:3-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-5-Methyl-1H-indole;
The fluoro-3-of code name 22:5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles;
The chloro-3-of code name 23:5-(2-(4-((2,3-dihydro-2-phenyl benzo [b] [Isosorbide-5-Nitrae] diox-3-base) methyl) piperazine-1-base) propyl group)-1H-indoles.
8. the Benzodioxane derivative according to any one of claim 1 ~ 7, it is characterized in that, described medically acceptable salt is selected from hydrochloride, hydrobromate, hydriodate, nitrate, vitriol, hydrosulfate, phosphoric acid salt, acid phosphate, acetate, lactic acid salt, Citrate trianion, tartrate, maleate, fumarate, mesylate, gluconate, saccharate, benzoate, esilate, benzene sulfonate or tosilate.
9. a pharmaceutical composition, comprises the Benzodioxane derivative described in any one of claim 1 ~ 8 for the treatment of significant quantity.
10. the application of the Benzodioxane derivative described in any one of claim 1 ~ 8 in preparation treatment or prevention Nervous and mental diseases medicine.
11. application according to claim 10, it is characterized in that, described Nervous and mental diseases is selected from mental disorder, anxiety disorder, personality disorder, dysthymia disorders, manic disorder, migraine, epilepsy or convulsive disorder, childhood disorder, Parkinson's disease, cognitive disorder, neurodegeneration or neurotoxicity.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210150420.9A CN103420989B (en) | 2012-05-15 | 2012-05-15 | Benzodioxane derivative and application thereof |
| PCT/CN2013/075596 WO2013170741A1 (en) | 2012-05-15 | 2013-05-14 | Benzodioxane compound, composition comprising same and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210150420.9A CN103420989B (en) | 2012-05-15 | 2012-05-15 | Benzodioxane derivative and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103420989A CN103420989A (en) | 2013-12-04 |
| CN103420989B true CN103420989B (en) | 2016-03-23 |
Family
ID=49583135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210150420.9A Active CN103420989B (en) | 2012-05-15 | 2012-05-15 | Benzodioxane derivative and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103420989B (en) |
| WO (1) | WO2013170741A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104725359B (en) * | 2013-12-20 | 2017-05-03 | 广东东阳光药业有限公司 | Substituted piperazine compound as well as application method and application thereof |
| WO2016192657A1 (en) | 2015-06-03 | 2016-12-08 | Sunshine Lake Pharma Co., Ltd. | Substituted piperazine compounds and methods of use and use thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959283A (en) * | 1973-10-23 | 1976-05-25 | Laboratoire L. Lafon | Amino-derivatives of 1,4-benzodioxan |
| CN1073173A (en) * | 1991-09-14 | 1993-06-16 | 史密丝克莱恩比彻姆有限公司 | Preparation method as the compound of 5-hydroxytryptamine receptor antagonist |
| CN1085217A (en) * | 1992-08-11 | 1994-04-13 | 默克专利股份有限公司 | 1,4-benzodioxan derivative |
| CN1089946A (en) * | 1992-09-10 | 1994-07-27 | 史密丝克莱恩比彻姆有限公司 | Medicine |
| CN1092422A (en) * | 1992-11-05 | 1994-09-21 | 史密丝克莱恩比彻姆有限公司 | Medicine |
| WO1997043259A1 (en) * | 1996-05-10 | 1997-11-20 | Monash University | Arylalkylpiperazine compounds as antioxidants |
| CN1265107A (en) * | 1997-07-25 | 2000-08-30 | H·隆德贝克有限公司 | Indole and 2,3-dihydronindole derivatives, their prepn. and use |
| CN101970436A (en) * | 2008-03-14 | 2011-02-09 | 默克专利股份有限公司 | Azaindole compounds for treatment of central nervous system disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1089997A1 (en) * | 1998-06-19 | 2001-04-11 | H.Lundbeck A/S | 4,5,6 and 7-indole and indoline derivatives, their preparation and use |
-
2012
- 2012-05-15 CN CN201210150420.9A patent/CN103420989B/en active Active
-
2013
- 2013-05-14 WO PCT/CN2013/075596 patent/WO2013170741A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959283A (en) * | 1973-10-23 | 1976-05-25 | Laboratoire L. Lafon | Amino-derivatives of 1,4-benzodioxan |
| CN1073173A (en) * | 1991-09-14 | 1993-06-16 | 史密丝克莱恩比彻姆有限公司 | Preparation method as the compound of 5-hydroxytryptamine receptor antagonist |
| CN1085217A (en) * | 1992-08-11 | 1994-04-13 | 默克专利股份有限公司 | 1,4-benzodioxan derivative |
| CN1089946A (en) * | 1992-09-10 | 1994-07-27 | 史密丝克莱恩比彻姆有限公司 | Medicine |
| CN1092422A (en) * | 1992-11-05 | 1994-09-21 | 史密丝克莱恩比彻姆有限公司 | Medicine |
| WO1997043259A1 (en) * | 1996-05-10 | 1997-11-20 | Monash University | Arylalkylpiperazine compounds as antioxidants |
| CN1265107A (en) * | 1997-07-25 | 2000-08-30 | H·隆德贝克有限公司 | Indole and 2,3-dihydronindole derivatives, their prepn. and use |
| CN101970436A (en) * | 2008-03-14 | 2011-02-09 | 默克专利股份有限公司 | Azaindole compounds for treatment of central nervous system disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103420989A (en) | 2013-12-04 |
| WO2013170741A1 (en) | 2013-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8822462B2 (en) | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | |
| EP2865381A1 (en) | ITK inhibitors for treating blood cell malignancies | |
| CN101304994B (en) | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | |
| WO2010115279A1 (en) | Kinase inhibitors and method of treating cancer with same | |
| KR20100133016A (en) | Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71 | |
| TW200819444A (en) | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | |
| CN109280030B (en) | Benzazaylalkyl aryl piperazine derivative and application thereof in preparing medicines | |
| CN101589042A (en) | The N of pharmacologically active, 3 of N '-replacement, 7-diazabicylo [3.3.1] nonane, based on its pharmaceutical composition and application method thereof | |
| JP6789578B2 (en) | 5-HT2C receptor agonists and compositions, and usage | |
| CN104080777B (en) | As the morpholinyl-derivatives of MOGAT-2 inhibitor | |
| Pompeu et al. | Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579 | |
| CN103420989B (en) | Benzodioxane derivative and application thereof | |
| BR112015000459B1 (en) | PHOSPHODIESTERASE 10 ENZYME INHIBITORS, THEIR USE, PHARMACEUTICAL COMPOSITION INCLUDING THEM, THEIR PREPARATION PROCESS AND PRODUCT | |
| CN101679400B (en) | Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound | |
| CN102267971A (en) | Alicyclic-o[c] benzopyrone derivative and application thereof | |
| CN103360342B (en) | 3-cyano-aniline alkylaryl bridged piperazine derivatives and preparing the application in medicine | |
| CN104059046A (en) | Flavonoid derivative and application thereof | |
| CN102267966B (en) | Substituted benzopyrone derivatives and application thereof | |
| CN103242219B (en) | 2,6-diketone-piperazine (piperidines) analog derivative and application thereof | |
| CN104177324B (en) | Xanthone compound and antidepressant application thereof | |
| CN107737126B (en) | Application of coumarin-dithiocarbamate derivative in pharmacy | |
| CN109280037B (en) | 3-cyanophenoxyalkyl aryl piperazine derivative and application thereof in preparing medicines | |
| CN110498789B (en) | Aralkyl piperidine derivative and application thereof in multi-target anti-depression | |
| CN109232549B (en) | Compound for treating schizophrenia and application thereof | |
| CN103965186B (en) | Benzodioxan-Ben Bing Evil (thiophene) azoles piperidine derivative and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |